- 0O59, SNY Ticker
- 🇬🇧 LSE, 🇺🇸 NASDAQ Exchange
- 104,226 Employees
- 💊 Health Care Sector
- 👩🏻⚕ Pharmaceuticals Industry
- Olivier Brandicourt CEO
45 rated
comming soon
comming soon
comming soon
comming soon
comming soon
comming soon
comming soon
comming soon
comming soon
Financial statements — Sanofi
The information is not 100% up-to-date. There may be errors or missing information. Some information is often missing, and, although there are almost no errors, I can't rule them out. Right now, I'm looking for a supplier of high-quality information, but so far what I'm finding is expensive (about $2000 a year). You can help my project here.
| 20 ← 16 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|
| Total Revenue |
|
46B | 42B | 41B | 43B | 37B |
| Cost Of Revenue |
|
15B | 13B | 13B | 14B | 11B |
| Gross Profit |
|
31B | 29B | 28B | 29B | 25B |
| Research and Development |
|
6.8B | 6.7B | 6.7B | 6.5B | 5.5B |
| Selling General and Admin |
|
12B | 11B | 11B | 12B | 10B |
| Operating Expense |
|
37B | 35B | 34B | 35B | 29B |
| Operating Income |
|
8.8B | 7.2B | 6.6B | 8.3B | 7.6B |
| Other Income Expense Net |
|
860M | 920M | 550M | 280M | 370M |
| EBIT |
|
10B | 8.4B | 7.7B | 8.7B | 8.1B |
| Interest Income |
|
410M | 240M | 310M | 330M | 230M |
| Pretax Income |
|
17B | 3.4B | 5.6B | 6.7B | 6.1B |
| Income Tax |
|
2.2B | 160M | 550M | 2.1B | 1.4B |
| Minority Interest |
|
44M | 35M | 120M | 140M | 96M |
| Net Income |
|
15B | 3.1B | 4.9B | 10B | 5B |
| Net Income Basic |
|
15B | 3.1B | 4.9B | 10B | 5B |
| 20 ← 16 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|
| Current cash |
|
18B | 11B | 8.1B | 12B | 11B |
| Short term investments |
|
2.2B | 2.3B | 2.4B | 560M | 470M |
| Receivables |
|
11B | 9.7B | 9B | 10B | 9.6B |
| Inventory |
|
10B | 9B | 8.5B | 8.1B | 7.3B |
| Other current assets |
|
2.2B | 2.3B | 2.4B | 560M | 470M |
| Current assets |
|
41B | 32B | 28B | 31B | 28B |
| Long term investments |
|
99B | 94B | 99B | 88B | 82B |
| Property plant equipment |
|
12B | 11B | 11B | 11B | 11B |
| Goodwill |
|
55B | 50B | 51B | 48B | 43B |
| Intangible assets |
|
23B | 19B | 25B | 16B | 11B |
| Other assets |
|
4B | 3.4B | 2.6B | 1B | 960M |
| Total assets |
|
140B | 130B | 130B | 120B | 110B |
| Accounts payable |
|
6.5B | 6B | 5.8B | 5.5B | 4.5B |
| Current long term debt |
|
3.7B | 5.4B | 3B | 1.5B | 1.9B |
| Other current liabilities |
|
13B | 11B | 11B | 11B | 11B |
| Total current liabilities |
|
24B | 23B | 20B | 18B | 17B |
| Long term debt |
|
25B | 24B | 25B | 17B | 18B |
| Other liabilities |
|
11B | 10B | 9.8B | 11B | 9.3B |
| Minority Interest |
|
660M | 760M | 1.3B | 1.4B | 1.6B |
| Total Liabilities |
|
63B | 60B | 60B | 50B | 50B |
| Common stock |
|
2.5B | 2.5B | 2.5B | 2.5B | 2.6B |
| Retained earning |
|
74B | 58B | 0 | 0 | 0 |
| Treasury stock |
|
-870M | -10M | -170M | -17M | -1.6B |
| Capital surplus |
|
• | • | • | • | • |
| Shareholder equity |
|
77B | 66B | 67B | 69B | 61B |
| Net tangible assets |
|
270M | -2.4B | -8.3B | 5.7B | 6.7B |
| 20 ← 16 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|
| Net Income |
|
15B | 3.1B | 4.9B | 10B | 5B |
| Depreciation |
|
4.5B | 8.4B | 4.9B | 4.4B | 3.5B |
| Changes in receivables |
|
1B | 700M | -1.3B | 800M | -100M |
| Changes in inventories |
|
1.3B | 410M | 410M | 860M | 170M |
| Cash change |
|
7.2B | 2.9B | -4.3B | 1.5B | 880M |
| Cash flow |
|
9.2B | 8.7B | 6.3B | 8.8B | 8.6B |
| Capital expenditures |
|
-2.6B | -2B | -2.3B | -2.3B | -2.2B |
| Investments |
|
• | • | • | • | • |
| Investing activity other |
|
• | • | • | • | • |
| Total investing cash flows |
|
-4.4B | -1.4B | -15B | -3.5B | -2.8B |
| Dividends paid |
|
• | • | • | • | • |
| Net borrowings |
|
8.7B | 16B | 18B | 5.7B | 8.3B |
| Other financing cash flows |
|
• | • | • | • | • |
| Cash flow financing |
|
-8B | -4.7B | 4.5B | -9.4B | -4.2B |
| Exchange rate effect |
|
• | • | • | • | • |
Engages in the research, production and distribution of pharmaceutical products